Evotec and Novo Nordisk enter into technology development …
WEBBoth Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies. In order to provide next-generation off-the-shelf cell therapy products for clinical development and possible commercialisation thereafter, the companies will collaborate on development of advanced technologies in support thereof.
Evotec and Novo Nordisk in technology development partnership
WEB1 day ago · German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support clinical and commercial manufacturing of stem cell-based therapies ...
Evotec and Novo Nordisk Enter into Technology Development …
WEB1 day ago · Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE ...
Novo, Evotec Ink Stem Cell Partnership as Drugmaker Looks to …
WEB23 hours ago · While the companies did not reveal the financial details of the deal, Novo Nordisk will provide funding for two Evotec sites in Germany and Italy to support the development of next-generation cell therapies.
EQS-News: Evotec and Novo Nordisk enter into technology …
WEB1 day ago · Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies 26.09.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this ...
Evotec and Novo Nordisk form strategic research alliance in …
WEBAug 22, 2018 · Evotec will apply its drug discovery platform, especially in ligand-based design, to seek to design novel, safe and efficacious products to address diabetes and associated morbidities. Once suitable pre-clinical candidates are selected, Novo Nordisk will use Evotec’s INDiGO platform to move through …
Evotec and Novo Nordisk form strategic alliance to develop …
WEBAug 18, 2020 · Evotec and Novo Nordisk will jointly identify and develop novel targets based on comprehensive medical and molecular data sets of thousands of chronic kidney disease patients.
News details - Novo Nordisk
WEBSep 26, 2023 · Novo Nordisk and Evotec collaborate to launch LAB eN², a translational drug discovery accelerator, to address innovation gap in cardiometabolic diseases. LAB eN ² will involve institutions including Harvard University, Mass General Brigham, and Beth Israel Deaconess Medical Center.
Evotec and Novo Nordisk enter into technology deve…
WEB1 day ago · EQS-News: Evotec SE / Key word (s): MiscellaneousEvotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies 26.09.2024 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. Novo Nordisk will provide funding...
EQS-News: Evotec and Novo Nordisk enter into technology …
WEB1 day ago · EQS-News: Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies Sep 26 2024 06:30 BST Source: EQS
- Some results have been removed